top of page

Publications, journal articles, and book chapters by Professor Ben Parker; Rheumatology Manchester.

Publications: Image

Publications, journal articles, and book chapters.

National Policies and National Clinical Guidelines.

1.  NICE Guidance 100: Rheumatoid Arthritis in Adults: management. 2018. Role: NG Committee member.

2.  NICE Technology Appraisal 415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor. 2017. Role: BSR Clinical Expert.

3.  NICE Technology Appraisal 375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis. 2016. Role: BSR Clinical Expert.

Peer reviewed journal articles.

  1. Early infection risk in patients with SLE treated with rituximab or belimumab from BILAG-Biologics register: a prospective observational study. The Lancet Rheumatology 2023.

  2. Predictors of BILAG-based outcomes in patients with SLE: analysis of from the SLICC inception cohort. Lupus 2023.

  3. SLE phenotypes formed from machine learning with a specific focus on cognitive impairment. Rheumatology. 2022

  4. Molnupiravir vs. placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK: a randomised, placebo-controlled, double blind trial (AGILE-CST-2). The Lancet Infectious Diseases. 2022.

  5. Predicting progression from uCTD to definite CTD: a systematic review and meta-analysis. Autoimmunity reviews. 2022.

  6. Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? The Lancet 400. 2022.

  7. The effects of disease activity on neuronal and behavioural cognitive processes in SLE. Rheumatology 2022.

  8. Effectiveness of belimumab after rituximab in SLE: a RCT. Annals Internal Medicine. 2021.

  9. Pausing drugs and spacing vaccines: an open question. Lancet Rheumatology. 2021.

  10. Lupus clinical trial eligibility in a real-world setting: results from BILAG-BR. Lupus Sci Med. 2021.

  11. Robust SARS-cov-2-specific T cell immunity is maintained at 6 months following primary infection. Nature Immunology. 2021.

  12. Serological surveillance of SARS-cov-2: Six-month trends and antibody response in a cohort of public health workers. Journal of Infection. 2021.

  13. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. Mabs 2021.

  14. Characterising long COVID more than 6 months after acute infection in adults; prospective longitudinal cohort study, England.  Medrixv. 2021.

  15. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY). The Lancet 2021.

  16. Direct healthcare resource utilisation, health-related quality of life, and work productivity in patients with moderate rheumatoid arthritis: an observational study. BMC musculoskeletal disorders 2021.

  17. Translating research into clinical practice: QIP to halve non-adherence to methotrexate. Rheumatology 2021. 

  18. Type I interferon activity identifies a subgroup of CTD patients with haematological abnormalities and specific autoantibody profiles. Arthritis Res Ther. 2019

  19. The Future of Biosimilars: Maximising Benefits Across Immune-Mediated Inflammatory Diseases. 2020. Drugs.

  20. Altered cognitive function in SLE and associations with inflammation and functional and structural brain changes. 2019. Ann Rheum Dis.

  21. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther. 2018

  22. QRISK3 improves detection of cardiovascular disease risk in patients with SLE. Lupus Sci Med. 2018

  23. An exploration of factors associated with the use of glucocorticoids in the Systemic Lupus International Collaborating Clinics Inception Cohort. 2018. Rheumatology

  24. Short-term efficacy and safety of Rituximab therapy in refractory SLE: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology 2018.

  25. Predictive and prognostic factors influencing outcomes of rituximab in therapy SLE? A Systematic Review. Semin Arthritis Rheum. 2017.

  26. Clinician’s approaches to management of background therapy in SLE patients in clinical remission: Results of an international survey. Lupus Science & Medicine 2017

  27. The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Clinical Excellence Guidelines in England and Wales. Rheumatology 2017. 56.

  28. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGS cohort. Ann Rheum Dis 2017.

  29. Can We Identify Who Gets Benefit or Harm from Mycophenolate Mofetil in SLE? A Systematic Review. Semin Arthritis Rheumatism 2017

  30.  Longitudinal change in endothelial microparticle count is associated with mortality in chronic kidney disease. Nephron. 2017.

  31. Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. Clinical radiology 2016.

  32. Microparticle Subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of Connective Tissue Disease. BBA Clin. 2016.

  33. Endothelial microparticles: Pathogenic or passive players in endothelial dysfunction in autoimmune rheumatic diseases? Vascul Pharmacol. 2016.

  34. Cognitive dysfunction and functional Magnetic Resonance Imaging in SLE. Lupus 2015

  35. Impact of Early Disease Factors on Metabolic Syndrome In SLE: Data From An International Inception Cohort.  Ann Rheum Dis 2015.

  36. Clinical utility of random anti–tumour necrosis factor drug–level testing and measurement of antidrug antibodies on the long term treatment response in rheumatoid arthritis. Arthritis & Rheumatology 2015.

  37. Suppression of inflammation reduces endothelial microparticles in active SLE. Ann Rheum Dis. Ann Rheum Dis. 2014

  38. SLE and the Metabolic Syndrome. Lupus 2013

  39. Certolizumab pegol attenuates the proinflammatory state in endothelial cells in a manner that is atheroprotective. Clin Exp Rheumatol 2013

  40. Clinical Associations of Metabolic Syndrome in SLE: Data from an International Inception Cohort. Ann Rheum Dis 2013

  41. Investigation of rheumatoid arthritis genetic susceptibility markers in the Early Rheumatoid Arthritis Study (ERAS) provides further replication of the TRAF1/C5 association with radiological damage. J Rheumatol 2013.

  42. An analysis of the Metabolic Syndrome in SLE. Lupus 2011.

  43. The Metabolic Syndrome in SLE. Rheum Dis Clin North Am 2010.

  44. High dose methylprednisolone therapy for the treatment of severe SLE. Lupus 2007.

Case Reports.

  1. A Case of IgG4-Related Disease and Membranous Nephropathy Associated with Thrombospondin Type-1 Domain-Containing 7A. Glomerular Dis. 2022.

  2. Acute systemic lupus erythematous and antiphospholipid syndrome with cardiac complications. 2019. JACC: Case Reports.

  3. A case of rheumatoid vasculitis involving the gastro-intestinal tract in early disease. Rheumatology 2007.

Book Chapters. 

  1. Parker B, Bruce IN. SLE: Clinical markers, metrics, indices and clinical trials. Dubois Lupus Erythematosus and Related Syndromes, 2018. Updated 2022.

  2. Parker B, Bruce IN. Landmark Papers in SLE. Landmark Papers in Rheumatology. Ed. Watts R, Scott DGI. 1st Edition. 2015

Patient/Charitable Contributions.

1.  Lupus and the heart and lungs. LUPUS UK information booklet. 2017.

Regional Prescribing guidance.

1.  High cost drugs pathway for Psoriatic arthritis and ankylosing spondylitis. Greater Manchester Medicines Management Group 2020.

2.  High cost drugs pathway for prescribing in rheumatoid arthritis. Greater Manchester Medicines Management Group 2017.

Further papers by Prof. Ben Parker can be found here

Publications: About Us
bottom of page